Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 86538 | 118.865 |
09:34 ET | 57290 | 117.47 |
09:36 ET | 74848 | 116.16 |
09:38 ET | 40347 | 118.235 |
09:39 ET | 37542 | 119 |
09:41 ET | 38216 | 119.875 |
09:43 ET | 15564 | 118.755 |
09:45 ET | 21459 | 119.57 |
09:48 ET | 5629 | 119.4695 |
09:50 ET | 13701 | 119.1 |
09:52 ET | 6701 | 118.48 |
09:54 ET | 2527 | 118.86 |
09:56 ET | 12961 | 118.8 |
09:57 ET | 10383 | 118.8488 |
09:59 ET | 8824 | 119.19 |
10:01 ET | 9422 | 119.27 |
10:03 ET | 7702 | 119.305 |
10:06 ET | 4952 | 119.1 |
10:08 ET | 8415 | 119.185 |
10:10 ET | 7626 | 119.13 |
10:12 ET | 8868 | 119.58 |
10:14 ET | 6383 | 118.8374 |
10:15 ET | 11513 | 119.24 |
10:17 ET | 4511 | 118.9 |
10:19 ET | 2648 | 119.0399 |
10:21 ET | 4894 | 119.07 |
10:24 ET | 9940 | 119.44 |
10:26 ET | 18974 | 119.48 |
10:28 ET | 47606 | 119.81 |
10:30 ET | 9550 | 119.88 |
10:32 ET | 11374 | 119.5301 |
10:33 ET | 5317 | 119.75 |
10:35 ET | 3875 | 119.05 |
10:37 ET | 2786 | 119.37 |
10:39 ET | 3300 | 119.2165 |
10:42 ET | 4024 | 119.28 |
10:44 ET | 1900 | 119.4 |
10:46 ET | 1350 | 119.21 |
10:48 ET | 4293 | 119.63 |
10:50 ET | 1266 | 119.6261 |
10:51 ET | 2440 | 119.67 |
10:53 ET | 5458 | 119.405 |
10:55 ET | 873 | 119.67 |
10:57 ET | 3837 | 119.93 |
11:00 ET | 3807 | 119.7013 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 46.5B | -7.6x | --- |
ICON PLC | 27.8B | 41.2x | +4.68% |
Biogen Inc | 33.5B | 28.2x | -18.14% |
Biontech SE | 20.2B | 162.7x | --- |
Grifols SA | 6.8B | 26.1x | --- |
Alnylam Pharmaceuticals Inc | 33.0B | -95.6x | --- |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $46.5B |
---|---|
Revenue (TTM) | $5.2B |
Shares Outstanding | 383.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.66 |
EPS | $-15.66 |
Book Value | $36.27 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | 9.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -99.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.